*Medicines and Healthcare Products Regulatory Agency*

Report No: ***Insp GMP 28205/122298-0005 NCR***

# STATEMENT OF NON-COMPLIANCE WITH GMP

***Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer*** [1]

## Part 1

Issued following an inspection in accordance with :
Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:
The manufacturer: ***GLAXOSMITHKLINE (TIANJIN) COMPANY LIMITED (TEDA)***
Site address: ***65 FIFTH AVENUE, TEDA, TIANJIN, CN-300457, China***

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2015-06-25*** , it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC

[1] *The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.*

## Part 2

| Human Medicinal Products |
|---|

| 1 NON-COMPLIANT MANUFACTURING OPERATIONS | |
|---|---|
| Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary; | |
| **1.2** | **Non-sterile products** |
| | *1.2.1 Non-sterile products (processing operations for the following dosage forms)*<br>1.2.1.13 Tablets |
| **1.5** | **Packaging** |
| | *1.5.2 Secondary packing* |
| | *1.5.1 Primary Packing*<br>1.5.1.13 Tablets |
| **1.6** | **Quality control testing** |
| | *1.6.2 Microbiological: non-sterility*<br>*1.6.3 Chemical/Physical* |

## Part 3

| **1. Nature of non-compliance:** |
|---|
| A critical deficiency was cited with regards system failures to ensure that the manufacture of medicinal products were fit for their intended use, complied with the requirements of the Marketing Authorisation and did not place patients at risk due to inadequate safety, quality or efficacy. • Since 2005, the company identified tablet discoloration in the stability samples during the stability trials which did not meet the shelf life specification. No action was taken to assess the risk of the remaining products in the markets. Adverse trends in stability-indicating attributes were observed but not investigated. • Product impact assessments failed to ensure that the defective product was not potentially supplied to the user. • Failure to notify competent authorities on the discovery of defective products. • Failure to address the root cause due to ineffective CAPA. Also delay in CAPA implementation. • Failure to escalate the incident and conduct effective investigations in a timely manner. |
| **Action taken/proposed by the NCA**<br><br>**Withdrawal, of current valid GMP certificate No. UK GMP 28205 Insp GMP 28205/122298-0004**<br>Withdrawal of previous GMP Certificate No: UK GMP 28205 Insp GMP 28205/122298-0004<br><br>**Prohibition of supply**<br>The site has been issued a statement of non compliance and should not be named on any marketing authorisations whilst this statement remains in place.<br><br>**Others**<br>No further MA should be approved naming the site as manufacturer. |

| Products manufactured at site, if known | Products | Dosage Form | Reference Member State, National or EMA |
|---|---|---|---|
| **Human Medicinal Products** | ZANTAC - PL 02855/0081 | 75 RELIEF | UK NATIONAL |
| | ZANTAC - PL 02855/0082 | TABLETS 75MG | UK NATIONAL |
| | ZANTAC - PL 10949/0042 | TABLETS 150MG | UK NATIONAL |
| | ZANTAC - PL 10949/0043 | TABLETS 300MG | UK NATIONAL |
| | ZANTAC TAB 150mg | TABLETS 150MG | Austria |
| | ZANTAC TAB 150mg | TABLETS 150MG | Austria |
| | ZANTAC TAB 300mg | TABLETS 300MG | Austria |
| | ZANTAC TAB 300mg | TABLETS 300MG | Austria |
| | ZANTAC TAB 150MG | TABLETS 150MG | Belgium |
| | ZANTAC TAB 150MG | TABLETS 150MG | Belgium |
| | ZANTAC TAB 150MG | TABLETS 150MG | Belgium |
| | ZANTAC TAB 150MG | TABLETS 150MG | Belgium |
| | ZANTAC TAB 300MG | TABLETS 300MG | Belgium |
| | ZANTAC TAB 300MG | TABLETS 300MG | Belgium |
| | ZANTAC TAB 300MG | TABLETS 300MG | Belgium |
| | ZANTAC TAB 150MG | TABLETS 150MG | Denmark |
| | ZANTAC TAB 150MG | TABLETS 150MG | Finland |
| | ZANTAC TAB 300MG | TABLETS 300MG | Finland |
| | ZANTIC TAB 75MG | TABLETS 75MG | Germany |
| | ZANTIC TAB 75MG | TABLETS 75MG | Germany |
| | AZANTAC TAB 150MG | TABLETS 150MG | France |
| | AZANTAC TAB 300MG | TABLETS 300MG | France |
| | ZANTAC TAB 150MG | TABLETS 150MG | Greece |
| | ZANTAC TAB 150MG | TABLETS 150MG | Ireland |
| | ZANTAC TAB 300MG | TABLETS 300MG | Ireland |
| | ZANTAC TAB 75MG | TABLETS 75MG | Ireland |
| | ZANTAC TAB 75MG | TABLETS 75MG | Ireland |
| | ZANTAC TAB 75MG | TABLETS 75MG | Ireland |
| | ZANTAC TAB 150MG | TABLETS 150MG | Italy |
| | ZANTAC TAB 300MG | TABLETS 300MG | Italy |
| | ZANTAC TAB 150MG | TABLETS 150MG | Netherland |
| | ZANTAC TAB 300MG | TABLETS 300MG | Netherland |

| | | |
|---|---|---|
| ZANTAC TAB 150MG | TABLETS 150MG | Norway |
| ZANTAC TAB 150MG | TABLETS 150MG | Norway |
| ZANTAC TAB 300MG | TABLETS 300MG | Norway |
| ZANTAC TAB 75MG | TABLETS 75MG | Norway |
| ZANTAC TAB 75MG | TABLETS 75MG | Norway |
| ZANTAC TAB 150MG | TABLETS 150MG | Portugal |
| ZANTAC TAB 150MG | TABLETS 150MG | Portugal |
| ZANTAC TAB 300MG | TABLETS 300MG | Portugal |
| ZANTAC TAB 150MG | TABLETS 150MG | Poznan |
| ZANTAC TAB 300MG | TABLETS 300MG | Poznan |
| ZANTAC TAB 150MG | TABLETS 150MG | Sweden |
| ZANTAC TAB 300MG | TABLETS 300MG | Sweden |
| ZANTIC TAB 150MG | TABLETS 150MG | Switzerland |
| ZANTIC TAB 150MG | TABLETS 150MG | Switzerland |
| ZANTIC TAB 300MG | TABLETS 300MG | Switzerland |
| ZANTIC TAB 300MG | TABLETS 300MG | Switzerland |
| ZANTAC TAB 150MG | TABLETS 150MG | UK / Malta |
| ZANTAC TAB 300MG | TABLETS 300MG | UK NATIONAL |
| ZANTAC 75 RELIEF | TABLETS 75MG | UK NATIONAL |
| ZANTAC 75MG | TABLETS 75MG | UK NATIONAL |
| ZANTAC 75MG | TABLETS 75MG | UK NATIONAL |
| ZANTAC 75 RELIEF | TABLETS 75MG | UK NATIONAL |

***2015-10-23***

Name and signature of the authorised person of the Competent Authority of United Kingdom

---

***Confidential***
***Medicines and Healthcare Products Regulatory Agency***
Tel: ***Confidential***
Fax: ***Confidential***